Edition:
United Kingdom

Acorda Therapeutics Inc (ACOR.OQ)

ACOR.OQ on NASDAQ Stock Exchange Global Select Market

30.35USD
8:04pm BST
Change (% chg)

$-0.20 (-0.65%)
Prev Close
$30.55
Open
$30.65
Day's High
$30.65
Day's Low
$30.25
Volume
32,161
Avg. Vol
165,995
52-wk High
$36.25
52-wk Low
$16.55

Select another date:

Wed, May 2 2018

BRIEF-Acorda Therapeutics Reports Q1 Non-GAAP Earnings Per Share Of $0.14

* ACORDA PROVIDES FINANCIAL AND PIPELINE UPDATE FOR FIRST QUARTER 2018

BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer

* AXSOME THERAPEUTICS APPOINTS NICK PIZZIE, CPA, MBA, AS CHIEF FINANCIAL OFFICER

BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer

* ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER

BRIEF-Acorda Files Marketing Authorization Application For Inbrija

* ACORDA FILES MARKETING AUTHORIZATION APPLICATION FOR INBRIJA™ (LEVODOPA INHALATION POWDER)

BRIEF-Leap Therapeutics Provides Dkn-01 Program Update

* LEAP THERAPEUTICS PROVIDES DKN-01 PROGRAM UPDATE AND ANNOUNCES SCIENTIFIC PRESENTATIONS AT AACR ANNUAL MEETING

BRIEF-Acorda Enters Into Cooperation Agreement With Scopia

* ACORDA THERAPEUTICS INC - ‍ UNDER TERMS, AFTER 2018 ANNUAL MEETING AND UNTIL JAN 1, 2019, SCOPIA IS ENTITLED TO APPOINT 2 DIRECTORS TO CO'S BOARD​

BRIEF-Acorda Announces FDA Acceptance Of New Drug Application For Inbrija

* ACORDA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR INBRIJA™ (LEVODOPA INHALATION POWDER)

BRIEF-Acorda Therapeutics Q4 Adj Shr $0.61

* AMPYRA NET REVENUE IS EXPECTED TO BE $330 MILLION TO $350 MILLION IN 2018

Acorda Therapeutics exploring sale: WSJ

Acorda Therapeutics is exploring a sale of the company, the Wall Street Journal reported, citing people familiar with the matter.

BRIEF-Acorda Therapeutics Is Exploring A Potential Sale - WSJ, Citing Sources

* ACORDA THERAPEUTICS IS EXPLORING A POTENTIAL SALE - WSJ, CITING SOURCES Source text - http://on.wsj.com/2Ay49BA Further company coverage: (Bengaluru Newsroom)

Select another date: